Evidence map›Paper›PMID 25454774›Full record

ReviewCell calcium2014

The mitochondrial permeability transition pore and its adaptive responses in tumor cells.

Andrea Rasola, Paolo Bernardi

Open access · hybridAbstract readReview
In one paragraph

Review in Cell calcium, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 90 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Novel Therapeutic Approaches of Ion Channels and Transporters in Cancer.Reviews of physiology, biochemistry and pharmacology · 2022
    Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Pharmacological modulation of mitochondrial ion channels.British journal of pharmacology · 2019
    Review
  15. Review
  16. Article
  17. Targeting Mitochondrial Ion Channels to Fight Cancer.International journal of molecular sciences · 2018
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Andrea RasolaDepartment of Biomedical Sciences and CNR Neuroscience Institute, University of Padova, Italy. Electronic address: rasola@bio.unipd.it.
Paolo BernardiDepartment of Biomedical Sciences and CNR Neuroscience Institute, University of Padova, Italy. Electronic address: bernardi@bio.unipd.it.
Neuroscience Institute · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review covers recent progress on the nature of the mitochondrial permeability transition pore (PTP) - a key effector in the mitochondrial pathways to cell death - and on the adaptive responses of tumor cells that desensitize the PTP to Ca(2+) and reactive oxygen species (ROS), thereby playing an important role in the resistance of tumors to cell death. The discovery that the PTP forms from dimers of F-ATP synthase; and the definition of the Ca(2+)- and ROS-dependent signaling pathways affecting the transition of the F-ATP synthase from an energy-conserving to an energy-dissipating device open new perspectives for therapeutic intervention in cancer cells.

Indexed as

Adaptation, PhysiologicalAnimalsApoptosisCalciumHumansMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PoreMitochondrial Proton-Translocating ATPasesNeoplasmsReactive Oxygen SpeciesSignal TransductionCalciumMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PoreMitochondrial Proton-Translocating ATPasesReactive Oxygen SpeciesCancerF-ATP synthaseMitochondriaPermeability transitionReactive oxygen species

Identifiers

PMID25454774
PMCPMC4274314
OpenAlexW2039652482

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.